ClinicalTrials.gg
Active, not recruitingNCT04251741ADDORA-switchUpdated Nov 18, 2023

Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment

A Phase 4 interventional study of Adalimumab trough concentration and Usual care in Rheumatoid Arthritis, sponsored by Reade Rheumatology Research Institute. Active, not recruiting at 2 sites in Netherlands. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Reade Rheumatology Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Arthritis, Rheumatoid with a site in Netherlands — 17 open to participants now, 26 under way, 1 of them phase 3. Arthritis, Rheumatoid · Netherlands.

Enrollment
79th of 130
86 · median 150
Started
2020
with 6 others
Phase 4
23 of 154
6 open now
Primary completion
2024-05
later than 2 of 25 live
Registered
130th of 154
by date
Lead sponsor
4 of 154
Reade Rheumatology Research Institute

Among the 154 studies in Arthritis, Rheumatoid with a site in Netherlands, this one is the 79th largest by enrollment of the 130 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 4, reaches primary completion later than 2 of the 25 other live ones, and was the 130th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

17 of the 154 studies in Arthritis, Rheumatoid with a site in Netherlands are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Netherlands, or all of them as a file.
02

Study summary

A potential application of therapeutic drug monitoring is to predict efficacy after switch to another biological in the case of inefficacy of the previous TNF-inhibitor (TNFi) in rheumatoid arthritis (RA) patients. It has been shown that when antidrug antibodies against adalimumab are detected (resulting in lower drug serum concentrations) in patients failing adalimumab, a normal response to a next TNF blocker can be anticipated. However, when clinical response is unsatisfactory and no antidrug antibodies against the first TNFi are detected (generally drug levels are adequate in this case), this predicts a lower response to a next TNFi. This means drug resistant failure in the former, compared to class resistant failure in latter category of patients. The current RA treatment strategy after failure of the first TNF-inhibitor is to start either a second TNFi or a non-TNFi. However, by channelling patients with sufficient adalimumab concentration to a non-TNFi will provide higher chance of disease control. Patients with very low or undetectable drug levels have an equal or potential higher chance of disease control with a drug of the same class (i.e. another TNFi).

Read the detailed description

Over the last decades biopharmaceuticals such as agents against tumor necrosis factor (TNF), are frequently prescribed to optimize rheumatoid arthritis treatment. Although TNFi such as adalimumab, etanercept and infliximab, have improved the treatment of rheumatoid arthritis, a proportion of patients discontinue the treatment because of inefficacy or intolerance.

Where TNFi have failed, mainly two treatment approaches are available: switch to another TNFi or to a biological with a different mode of action (notably rituximab, abatacept or tocilizumab) or to a target synthetic DMARDs. The EULAR recommendation for the management of rheumatoid arthritis advocate that any biologic agent including a subsequent TNFi can be used with equal chance for effect in case of non-response to a previous TNFi. This recommendation is based on three randomized controlled trails, but it should be noted that systematic reviews also including non-randomized controlled studies sometimes concluded that non-TNFi are more effective after TNFi failure than a second TNFi.

Of note, currently there are no strong predictors available for response to bDMARDS in RA. This study focuses on non-response after adalimumab, as this is the most prescribed TNFi worldwide.

Although it seems that indeed on a group level response to a non-TNFi is comparable to a second TNFi after the first TNFi has failed, using therapeutic drug monitoring could identify subgroups of patient who would benefit more from either a non-TNFi or a TNF-i as next treatment. The underlying pathophysiological mechanisms for this hypothesis are explored in this study.

Nonresponse on adalimumab in RA can have different causes. Firstly, the patient might not be sensitive to TNF blockade at all, or the patient develops this trait later on (primary nonresponse or secondary nonresponse). In these patients, switching to a non-TNFi might conceptually be superior to starting a second TNFi. However, in other patients nonresponse (either primary or secondary) might be caused by inefficient drug concentration because of development of antidrug antibodies against adalimumab. In these patients a TNFi might be just as effective as a non-TNFi, as these patients have drug- but not class failure. Thus, testing of adalimumab levels might be helpful in channelling patients to their most optimal treatment.

Above mentioned hypothesis has been tested in three studies (5) of which one concerned adalimumab in RA. This study showed that response to a second TNFi was indeed higher in patients with antidrug antibodies (ADA) and low adalimumab levels, and lower in patients with adequate adalimumab levels. However, a diagnostic study comparing a serum concentration guided versus usual care switching strategy has not yet been performed.

In this multi-centre, double blinded randomized controlled trial it will be evaluated whether clinical outcome after switching to a subsequent biological treatment is superior with a switching strategy using adalimumab concentration compared to usual care switching strategy.

Patients with rheumatoid arthritis starting another bDMARD (biologic disease modifying antirheumatic drugs) after adalimumab failure (defined as DAS28-CRP >2.9) are randomly assigned to usual care (with randomized switch to etanercept or to a non-TNFi) or 'drug concentration' guided switch.

Data regarding disease status, functioning, adverse events and use of co-medication/rescue medication will be collected during this study.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Adalimumab
  • Rheumatoid arthritis
  • Therapeutic Drug Monitoring
  • Drug level
  • Switching
  • Failure
  • Non-response
  • Subsequent biological
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • rheumatoid arthritis patient, according to American College of Rheumatology (ACR) 1987 and/or EULAR/ACR 2010 criteria;
  • recently failed treatment with adalimumab (defined as DAS28-CRP >2.9) and not treated with a subsequent bDMARD or target synthetic DMARD (tsDMARD)
  • Received adalimumab for at least 10 weeks in standard dosing (40mg subcutaneously every other week, either in monotherapy or combined with methotrexate or leflunomide)
  • Stop adalimumab due to inefficacy, either alone or combined with side effects
  • who has agreed to participate (written );
  • age 16 years or older.

Exclusion criteria

Exclusion Criteria:

  • Treatment with another TNF-inhibitor prior to adalimumab
  • Treatment with all non-TNFi options (abatacept, rituximab, sarilumab and tocilizumab) prior to adalimumab
  • scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation
  • shorter than follow-up period of the study;
  • no possibility to safely receive an TNF-inhibitor or a non TNF-inhibitor
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Active comparator
    Usual care group

    Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)

    Other: Usual care

  • Experimental
    'Drug concentration guided' group

    Patients with a concentration \<1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)

    Diagnostic Test: Adalimumab trough concentration

Interventions

  • Diagnostic testAdalimumab trough concentration

    In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration

  • OtherUsual care

    In the usual care group, switch to subsequent biological is based on secondary randomisation

06

What researchers measure

Primary outcomes

  1. mean time weighted DAS28-CRP

    difference in mean time weighted DAS28-CRP between the two groups

    Time frame: 24 weeks

Secondary outcomes

  1. Good or moderate response according the EULAR response criteria

    Percentage of patients with good or moderate response according the EULAR response criteria

    Time frame: 12 en 24 weeks

  2. Minimal disease activity (DAS28-CRP<2.9)

    Percentage of patients with minimal disease activity (DAS28-CRP\<2.9)

    Time frame: 24 weeks

  3. Non-responders

    Percentage of patients with no response according to EULAR response criteria

    Time frame: 24 weeks

  4. Number of adverse events

    The number of adverse events

    Time frame: 24 weeks

  5. Severity of adverse events

    Severity of adverse events

    Time frame: 24 weeks

  6. Cumulative dose co-medication

    Cumulative dose of co-medication

    Time frame: 24 weeks

  7. Times co-medication is used

    Number of times co-medication is used

    Time frame: 24 weeks

  8. Cumulative dose of rescue medication

    Cumulative dose of rescue medication

    Time frame: 24 weeks

  9. Times rescue medication is used

    Number of times co-medication is used

    Time frame: 24 weeks

07

Study locations

2 sites
08

References and documents

Publications

  • Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. PubMed 28413099 ↗
  • Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007 Jan;56(1):13-20. doi: 10.1002/art.22331. PubMed 17195186 ↗
  • Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10. PubMed 21068090 ↗
  • L' Ami MJ, Ruwaard J, Krieckaert C, Nurmohamed MT, van Vollenhoven RF, Rispens T, Wolbink GJ. Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. Scand J Rheumatol. 2019 Jul;48(4):266-270. doi: 10.1080/03009742.2019.1577915. Epub 2019 Apr 23. PubMed 31012365 ↗

Individual participant data

Plan to share: Yes — To avoid duplication of research, the gathered data will be shared once all desirable data analysis have been performed and the results are published

Supporting information: Study protocol, Statistical analysis plan

Time frame: Six months after the study is published the data will be shared

Access criteria: Researchers with demonstrable interest in autoimmunity, biologicals, or therapeutic drug monitoring (TDM) can contact the investigators of the trial if they are interested in gaining access to the data. Depending on their research objectives the data will be shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for May 2024, 45 months after the start.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 45 months is close to that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2020
First posted
Feb 5, 2020
StartActual
Jul 31, 2020
Primary completionEst.
May 1, 2024
CompletionEst.
May 1, 2024
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04251741
Lead sponsor
Reade Rheumatology Research Institute
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Jul 31, 2020
Primary completion
May 1, 2024 (estimated)
Completion
May 1, 2024 (estimated)
Last update
Nov 18, 2023

Study contacts

Gertjan Wolbink, PhD
principal investigator · Reade Rheumatology Research Institute
Alfons A Den Broerder, PhD
principal investigator · Sint Maartenskliniek

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion